GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Notes Receivable

CTOR (Citius Oncology) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Notes Receivable?

Citius Oncology's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Citius Oncology Notes Receivable Historical Data

The historical data trend for Citius Oncology's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Notes Receivable Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Notes Receivable
- - -

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial - - - - -

Citius Oncology Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Citius Oncology Notes Receivable Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Oncology Business Description

Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.